116 related articles for article (PubMed ID: 30998140)
21. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target.
Zhang S; Zhang Q; Shi G; Yin J
Biomed Pharmacother; 2018 Jan; 97():1189-1194. PubMed ID: 29136958
[TBL] [Abstract][Full Text] [Related]
22. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
[TBL] [Abstract][Full Text] [Related]
23. THE ROLE GENE EXPRESSION OF PD-1 AND PD-L1 IN NEWELY DIAGNOSED AND TREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA.
Al-Saedi S; Hamzah I
Georgian Med News; 2023; (340-341):25-29. PubMed ID: 37805869
[TBL] [Abstract][Full Text] [Related]
24. [Value of BCL-2 and PD-L1 Combined Detection in Predicting the Prognosis of Primary Acute Leukemia].
Chen Z; Cai ZM; Zhao LD; Wang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1636-1640. PubMed ID: 29262889
[TBL] [Abstract][Full Text] [Related]
25. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Zhao L; Yu H; Yi S; Peng X; Su P; Xiao Z; Liu R; Tang A; Li X; Liu F; Shen S
Oncotarget; 2016 Jul; 7(29):45370-45384. PubMed ID: 27248318
[TBL] [Abstract][Full Text] [Related]
26. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
[TBL] [Abstract][Full Text] [Related]
27. Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility.
Brodská B; Otevřelová P; Kuželová K
Cancer Immunol Res; 2016 Oct; 4(10):815-819. PubMed ID: 27543594
[TBL] [Abstract][Full Text] [Related]
28. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
29. Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia.
Yan J; Wu G; Chen J; Xiong L; Chen G; Li P
Cancer Biomark; 2018; 22(1):73-78. PubMed ID: 29439315
[TBL] [Abstract][Full Text] [Related]
30. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients.
Butrym A; Rybka J; Baczyńska D; Tukiendorf A; Kuliczkowski K; Mazur G
J Exp Clin Cancer Res; 2015 Jul; 34(1):68. PubMed ID: 26126974
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
van Ens D; Mousset CM; Hutten TJA; van der Waart AB; Campillo-Davo D; van der Heijden S; Vodegel D; Fredrix H; Woestenenk R; Parga-Vidal L; Jansen JH; Schaap NPM; Lion E; Dolstra H; Hobo W
Bone Marrow Transplant; 2020 Dec; 55(12):2308-2318. PubMed ID: 32528120
[TBL] [Abstract][Full Text] [Related]
32. A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Zhou L; Fu L; Lv N; Chen XS; Liu J; Li Y; Xu QY; Huang S; Zhang XD; Dou LP; Wang LL; Li YH; Yu L
Eur Rev Med Pharmacol Sci; 2017 Feb; 21(4):786-794. PubMed ID: 28272704
[TBL] [Abstract][Full Text] [Related]
33. Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia.
Lin X; Wang Z; Wang Y; Feng W
Int J Clin Exp Pathol; 2015; 8(11):14658-66. PubMed ID: 26823789
[TBL] [Abstract][Full Text] [Related]
34. [Effect of PD-L1 Expression on Activity of NK Killing AML Cell Lines and Its Mechanisms].
Liu YF; He PC; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1317-1322. PubMed ID: 30295244
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Luo W; Yu H; Zou X; Ni X; Wei J
Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
[TBL] [Abstract][Full Text] [Related]
36. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
[TBL] [Abstract][Full Text] [Related]
37. Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia.
Tian C; Zhang L; Li X; Zhang Y; Li J; Chen L
Cancer Biomark; 2018; 22(2):209-215. PubMed ID: 29689705
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
[TBL] [Abstract][Full Text] [Related]
39. [Expression of Programmed Death Ligand-1 (PD-L1) in Human Acute Leukemia and Its Clinical Significance].
Zhang ZF; Zhang QT; Xin HZ; Gan SL; Ma J; Liu YF; Xie XS; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):930-4. PubMed ID: 26314420
[TBL] [Abstract][Full Text] [Related]
40. [Expression of HOXB4, PRDM16 and HOXA9 in Patients with Acute Myeloid Leukemia and Its Clinical Significance].
Li L; Zhao CT; Cui BL; Wu SL; Liu XD; Su Z; Yang J; Wang W; Cui ZG; Zhao HG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):326-31. PubMed ID: 27150986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
